ProAlgaZyme Novel Algae Infusion: Applications in Metabolic Syndrome

Status Completed

Clinical Trial Summary

The purpose of this study is to compare the effects of supplementation with ProAlgaZyme (a novel fermentation product of a freshwater algae ecosystem) vs. placebo on Metabolic Syndrome and indicators of cardiovascular health including: body weight and fat, blood lipids, inflammatory markers such as hsCRP, blood pressure and fasting blood glucose.

Clinical Trial Description

Metabolic syndrome, a set of symptoms strongly associated with increased risk for both cardiovascular disease and diabetes, is generally linked to obesity and has become a serious problem in many industrialized countries. Agents that aid in weight loss or help to normalize blood lipids or inflammation may reduce the risk of metabolic syndrome and therefore, reduce the risk of cardiovascular disease and diabetes. This study is a single-center, double-blind, placebo-controlled, parallel design, to evaluate the effects of ProAlgaZyme (4 fl. oz. daily) on metabolic syndrome and markers of cardiovascular health including blood lipids, inflammatory markers and anthropometric measurements.

Comparisons: ProAlgaZyme vs. placebo [Time frame: 10 weeks] ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00489333
Study type	Interventional
Source	Health Enhancement Products, Inc.
Contact
Status	Completed
Phase	N/A
Start date	May 2006
Completion date	September 2006

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02702375` - Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases	N/A
Completed	`NCT02918422` - Controlled Clinical Study to Determine Novel Health Benefits of Cheese Consumption	N/A
Completed	`NCT02649348` - Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome	N/A
Completed	`NCT02356952` - Effect of a Low Glycemic Index on Metabolic Syndrome	N/A
Completed	`NCT02337933` - Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome	Phase 2
Completed	`NCT02459691` - Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos)	N/A
Completed	`NCT02402985` - Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics	N/A
Completed	`NCT01694056` - Soy Protein Intake and the Metabolic Syndrome	N/A
Completed	`NCT00344903` - Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort	N/A
Recruiting	`NCT00408824` - Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study)	N/A
Completed	`NCT00362908` - Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome	N/A
Completed	`NCT00395486` - ROMEO (Rosuvastatin in Metabolic syndrOme)	Phase 4
Completed	`NCT00140816` - Dairy Products and Metabolic Effects (Norwegian Part)	N/A
Completed	`NCT00101517` - Partnership Programs to Reduce Ethnic Differences in the Risk of Cardiovascular Disease	N/A
Completed	`NCT00455325` - Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)	Phase 2
Completed	`NCT00166036` - Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells	Phase 2
Recruiting	`NCT00177892` - Obstructive Sleep Apnea (OSA) and Metabolic Syndrome: Role of Oxidative Stress	N/A
Completed	`NCT00073775` - Epidemiology of Stress and the Metabolic Syndrome	N/A
Completed	`NCT00074451` - Genomewide Search for Loci Underlying Metabolic Syndrome
Completed	`NCT00200993` - Peripheral Effects of Exercise on Cardiovascular Health (STRRIDE I)	Phase 2